Disclose an Invention

Submit

Connect with UIRF

Join our inventor office hour the first Tuesday of every month from 4-5pm.

Connect via Zoom

View Available Technologies

view

Attend a Class

Learn about intellectual property, licensing, and commercialization at one of our virtual classes.

Learn More

Unsure where to start?

Our staff are here to help guide UI innovators who want to commercialize new innovations.

 

Learn about our process

Latest Innovations

Enhancing Antibody Dependent Cellular Cytotoxicity

A Novel Method to Make Wettability Pattern for Metal Surfaces

Novel Molecules for the Prevention of Vascular Dysfunction

Multilevel Dynamic Regenerative Braking (DRB) System

News feed

Two companies co-founded by UI researchers secure a combined $62M in financing to advance disease therapies

Tuesday, June 21, 2022
Office of the Vice President for Research
The companies, Carbon Biosciences and hC Bioscience, are based on foundational research by University of Iowa (UI) professors John Engelhardt, Ziying Yan, Chris Ahern, and colleagues at other institutions.

Carbon Biosciences Launches with $38 Million Series A Financing to Advance Novel Gene Therapy Platform and Pipeline

Tuesday, June 21, 2022
Businesswire
Founded in part by University of Iowa gene therapy pioneers John F. Engelhardt, Ph.D. and Ziying Yan, Ph.D., along with Robert M. Kotin, Ph.D. and Longwood Fund, Carbon is expanding the gene therapy toolbox for the treatment of the world’s most devastating and difficult to treat diseases.

Mana Capital Acquisition Corp. and Cardio Diagnostics, Inc. Announce Definitive Business Combination Agreement to Create Publicly Listed Company Set to Transform Cardiovascular Disease Through Epigenetics

Wednesday, June 1, 2022
Cardio Diagnostics, Inc.
Cardio Diagnostics, Inc. a UI start-up company and a pioneering precision cardiovascular medicine company, and Mana Capital Acquisition Corp., a special purpose acquisition company, announced that they have entered into a definitive business combination agreement that will result in Cardio Diagnostics becoming a publicly listed company.

Strong Demand for Lung Intelligence Accelerates VIDA's Growth

Wednesday, May 4, 2022
VIDA Diagnostics, Inc.
VIDA Diagnostics, Inc. (VIDA), a UI start-up company and the leader in lung and respiratory intelligence, announced it has secured financing as it scales up to support strong demand for its VIDA Intelligence Portal, an AI-powered solution that supports clinical trial decentralization and improves site recruitment, onboarding, staff training, image data management and data quality.

VIDA Expands Global Footprint into Japan with Market Authorization Through Partner Cairvo

Wednesday, April 13, 2022
PR Newswire
VIDA Diagnostics, Inc, a UI start-up and leader in lung and respiratory intelligence, has received market authorization in Japan for its VIDA Insights® software, paving the way for lung care teams to begin using the solution at the point of care.

47

New Licenses and options granted to UI technologies

FY2021

123

New patent applications

FY2021

101

New invention disclosures

FY2021